|
Angiotech Pharmaceuticals |
|
|
1618 Station Street
Vancouver, BC V6A 1B6 Canada
phone:(604) 221-7676
fax:(604) 221-2330
|
|
| Symbol |
ANPI |
| Exchange |
Nasdaq |
| Founded |
1992 |
| Employees |
50 |
|
|
| www.angiotech.com
|
|
| Research Sector |
Healthcare Services |
|
 |
| Summary Description |
| Specialty pharmaceutical company focused on pharmacotherapeutics. |
|
| Management |
| William Hunter, President and Chief Executive Officer; Rui Avelar, Chief Medical Officer; Steven Bryant, Senior Vice President, Sales & Marketing, Specialty Medical Devices ; K. Thomas Bailey, Chief Financial Officer; Sean Cunliffe, Senior Vice President, Sales & Marketing |
| |
|
|
|
|
|
|
|
| Keywords |
| ophthalmology, microsurgery, anti-infective hemoStream, multiStem, lung biopsy |
|
|
|
| Description |
|
It is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. They are listed on both the TSX and NASDAQ stock exchanges (TSX: ANP, NASDAQ: ANPI). They look for compounds that address the underlying biological causes of conditions that can occur concurrently with medical device implantation, surgery or acute trauma. |
|
| Products / Services |
Paclitaxel, Drug-Eluting Stents, Drug-Loaded Vascular Wrap, Surgical Adhesions, Surgical Sealants, Surgical Hemostats.
|
|
| Technology / Differentiation |
| It is a novel technology designed to prevent air leaks in patients having lung biopsies by plugging the biopsy track with an expanding hydrogel plug. On contact with moist tissue, the hydrogel plug absorbs fluids and expands to fill the void created by the biopsy needle puncture. The seal is airtight and the plug is absorbed into the body after healing of the puncture site has occurred. |
|
| Market / Customers |
Following the acquisition of American Medical Instruments Holdings, Inc. in 2006, Angiotech expanded beyond its strong R&D capabilities to include the manufacturing and marketing of a wide range of single use, specialty medical devices.
Today, in addition to its manufacturing capabilities, Angiotech has created specialized sales and marketing teams in North America, Europe, South America and Asia. Angiotech's sales and marketing teams are organized by their product groupings and focus on three key markets: Interventional, Surgical and Specialty/OEM.
Angiotech's Business Units:
* Angiotech Interventional
* Angiotech Surgical (including Wound Closure)
* Angiotech Specialty OEM
* Angiotech Specialties (including Ophthalmology, Dental, Microsurgery and Private Label)
Angiotech is working to accelerate growth of its existing business through expansion of its direct sales force and creation of a global distribution network. At the same time, Angiotech anticipates growth through the development and launch of exciting next-generation products, such as Quill' SRS, HemoStream' and SharpGuard'.
Angiotech is also re-positioning its OEM and private label business for continued growth by offering a comprehensive line of private label, finished medical devices and medical device components for third-party medical device manufacturers.
|
|
| Competitors / Substitutes / Alternatives |
Draxis Health Inc (DRAX), Ivax Corp (IVX), NeoPharm Inc (NEOL)
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members